Findings reveal fluoxetine's weak antiviral effects in COVID-19, with no significant benefits in symptom resolution compared to other antiviral treatments.
HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin ...